Hepatitis News : India Revokes Roche’s Patent for Hep C Drug Pegasys
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis News » November 2012


November 5, 2012

India Revokes Roche’s Patent for Hep C Drug Pegasys

In a landmark victory for patients’ rights groups, the Intellectual Property Appellate Board (IPAB) in India has revoked Roche’s patent on the hepatitis C virus (HCV) drug Pegasys (pegylated interferon alfa-2a) in that country, according to an article in Lawyer’s Collective. With a price tag of almost $9,000, Pegasys treatment is so prohibitively expensive in India that it is not even used in government hospitals. After Roche received the 2006 patent, which was the first drug patent awarded in India since 1970, an aid group for injection drug users, Sankalp, partnered with the Lawyers Collective HIV/AIDS Unit to challenge the patent.

Roche argued that Sankalp had no grounds to sue because it was not a business competitor, but IPAB ruled that, as a patients’ advocacy group, Sankalp is indeed directly affected by Roche’s monopoly on Pegasys’ sale. IPAB further ruled that there was insufficient evidence that Pegasys is superior to other hep C treatments. While Roche may still appeal, the ruling will likely open the door to generic competition. This could lower the cost of treatment enough to affect the estimated 12 million Indians, or 1 percent of the population, living with the virus.

For an article on this topic in Lawyers Collective, click here.

For an article in Business Today, click here.

Search: Hepatitis C, HCV, hep c, Roche, Pegasys, pegylated interferon alfa-2a, patent, Intellectual Property Appellate Board, IPAB, Lawyer?s Collective, Sankalp, India, revoke, generic, competition

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Do you know any young people (under age 30) who are currently living with hepatitis C?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.